aTYR PHARMA (ATYR) Total Liabilities (2014 - 2026)

aTYR PHARMA (ATYR) has reported Total Liabilities for 13 consecutive years, with $21.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 21.73% year-over-year to $21.0 million; the trailing twelve-month figure through Jun 2026 stood at $21.0 million (down 21.73% YoY), and the FY2025 full-year result was $25.5 million, down 5.46% from the prior year.
• Total Liabilities eased to $21.0 million in Q2 2026 per ATYR's latest filing, from $21.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $30.2 million in Q4 2023 and bottomed at $6.4 million in Q1 2022.
• Historically, Total Liabilities has averaged $23.4 million across 5 years, with a median of $26.0 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities jumped 323.93% in 2023, then dropped 22.73% in 2025.
• Over 5 years, Total Liabilities stood at $24.5 million in 2022, then rose by 23.19% to $30.2 million in 2023, then dropped by 10.55% to $27.0 million in 2024, then slipped by 5.46% to $25.5 million in 2025, then decreased by 17.58% to $21.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $21.0 million, $21.9 million, and $25.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.